On Mar. 24, 2020, PerkinElmer announced the U.S. Food and Drug Administration (FDA) had provided Emergency Use Authorization (EUA) for the Company’s New Coronavirus RT-PCR test.

Clinical laboratories certified under Clinical Laboratory Improvement Amendments (CLIA) immediately began using this kit to detect SARS-CoV-2, the virus that causes COVID-19.  PerkinElmers RT-PCR test is marketed as an in vitro diagnostic (IVD) device by meeting the requirements of the European In Vitro Diagnostic Directive (IVDD) and was available in over 30 countries worldwide.

PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise.